Skip to content
naulon

Not checkedNot checked for notices yet.

Neo-adjuvant chemotherapy in luminal, node positive breast cancer: characteristics, treatment, and oncological outcomes. A single center’s experience

E. Barbieri, D. Gentile, A. Bottini and 4 more

Breast · 2021

doi:10.1016/s0960-9776(21)00181-8 (opens in a new tab)

We email you when a new notice or a question about this paper appears.

Abstract

analysis showed a significant difference in pCR in relation to the ER/ PR/HER-2 grouping (either ER/PR positive = 63.64%,Triple positive = 34.15%,Enriched = 82.05%,Chi 2 19.2056, P < 0.00007).Factors not showing statistically significant differences in pCR were the initial tumor size, menopausal status, nodal status and use of adriamycin vs no adriamycin in the neoadjuvant chemotherapy regimen.Conclusion(s): This data highlights the importance of molecular subtyping and Ki 67 scores of early stage HER-2 breast cancers, as well as the importance of Trastuzumab based neoadjuvant chemotherapeutic regimens as HER-2 enriched subtypes attained a higher pCR rate than the other subtypes.Furthermore, this study emphasises the need for Trastuzumab to be made available to all patients with HER-2 enriched breast cancers in the neoadjuvant setting in South Africa.

Abstract licence: CC BY-NC

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.